Innovus Pharmaceuticals Inactive 10-Q2017 Q1 Quarterly report

Filed: 15 May 17, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: allergy, AllerVarx, alleviate, Amazon, announced, Apeaz, ArthriVarx, assist, back, bilayer, blank, card, center, check, Cleanse, Coffee, creditor, declared, dedicated, delay, delaying, Denmark, desire, discontinue, disease, Dubai, dysfunction, evergreen, Extract, face, favorable, forced, forfeiture, Green, HCW, HIK, Hikma, hiring, history, HKMPY, hold, hundred, import, impose, intercourse, Italy, joint, Korea, lead, leader, length, lesser, leverage, local, LSE, main, mcg, MENA, methyl, modification, NASDAQ, NDA, newly, NTC, nutritional, opportunity, outflow, outright, packaged, PEVarx, phone, PLC, policy, preferred, prescription, preventing, ProstaGorx, provision, pursuing, pursuit, reimbursement, relationship, relieve, remitted, restructuring, review, revolving, rx, salicylate, satisfy, scaling, segment, senior, shipment, simple, South, specialty, statutory, strength, switch, tablet, tested, thereof, tract, UAE, underwriter, underwriting, undesignated, urology, USP, valuable, Wainwright, withholding, writing, WWPIL

Removed: added, adjust, adjusted, Algeria, anniversary, applying, approach, Arab, Arabia, assessing, assigned, assumed, audit, authority, automatic, Benin, borrow, borrowed, BTH, Burkina, Cape, CFO, charge, CN, Coast, commitment, compliance, consecutive, consummated, cure, cycle, Damaj, delivered, department, detail, determine, determining, differentiated, discretion, domain, Dr, Egypt, establishment, expectation, extensive, Faso, fifteen, fifty, foregoing, foreign, funding, Gambia, Ghana, grow, guaranteed, Guinea, hedge, hedging, high, hour, identifiable, Imputation, imputed, indemnification, individually, intent, Iraq, Ivory, Jersey, Jordan, largest, Leone, Liberia, Libya, loan, LOC, low, lubricant, Mali, mature, meeting, month, multiplied, Niger, Nigeria, NJEDA, North, noted, notice, Notwithstanding, osmolality, percent, portion, practicable, previously, projected, proper, proven, provisional, qualify, range, relevant, remedy, represent, request, reset, returned, revised, Saudi, Senegal, Sierra, smaller, stockholder, Subtopic, sum, survive, sustain, tangible, terminate, Togo, trade, trading, treated, Tunisia, ultimate, uncertain, USD, Verde, viscosity, VWAP, waived, West

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Innovus Pharmaceuticals similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION REQUIRED BY

SECTION 1350 OF TITLE 18 OF THE UNITED STATES CODE

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, each of the undersigned hereby certifies in his capacity as the specified officer of Innovus Pharmaceuticals, Inc. (the “Company”), that, to the best of his knowledge, the Quarterly Report of the Company on Form 10-Q for the fiscal quarter ended March 31, 2017 fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, and that the information contained in such report fairly presents, in all material respects, the financial condition and results of operations of the Company as of the dates and for the periods presented in the financial statements included in such report.

Date: May 15, 2017

/s/ Bassam Damaj
Bassam Damaj, Ph.D. President, Chief Executive Officer and Director
(Principal Executive Officer)

Date: May 15, 2017

/s/ Rauly Gutierrez
Rauly Gutierrez, CPA Vice President, Finance
(Principal Financial Officer)

This certification accompanies this Report on Form 10-Q pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.